Human Centric Drug Discovery gains ISO 27001 certification
October 28th, 2022
We are delighted to announce that Human Centric Drug Discovery is now ISO 27001 certified! This is an internationally recognised standard, demonstrating our ongoing commitment to information security.
HCDD's all-female lab team is complete
October 27th, 2022
With the addition of Rowan Taylor, the Human Centric DD lab team is now complete. Rowan is a molecular and cell biologist with a research background in modelling human disease using stem cell-derived models. She also brings an in depth experience of using CRISPR-Cas9 gene editing to model disease in human cells. Following her PhD at the University of Leeds, Rowan is excited to start her research career at Human Centric DD. She will use her expertise in human disease modelling to drive innovative drug development for patients with neurological disorders.
We welcome a new addition to our lab team!
August 8th, 2022
Antigoni Katsikoudi has joined HCDD as a Research Scientist. She is a neuroscientist with a research background in modelling neurodegeneration using human relevant models of disease. She brings an in-depth experience of the neurological drug discovery pipeline having previously worked in an international pharmaceutical company. Having recently completed her DPhil degree she brings to the company fresh expertise in developing and optimising human stem cell assays.
HCDD celebrates the opening of our laboratories in Oxford
July 26th, 2022
We celebrate the opening of our laboratories at the Wood Centre for Innovation in Oxford. James Peach, CEO opened the laboratories by ribbon cutting followed by a party at the terrace to celebrate with other companies in the building. We are looking forward to getting started with cell cultures to understand and treat neurological disorders.
Human Centric DD welcomes experienced lead scientist
May 11th, 2022
Human Centric Drug Discovery welcomes Dr. Rosa Woldegebriel, PhD as a Lead Scientist. She is an experienced neuroscientist and cell biologist with core expertise in using human stem cells for neurological disease modelling. She has previously co-founded a start-up focusing on using real-world data in healthcare. She now has responsibility for leading the research aspects of the company, working with the CSO. She is delighted to begin her work with HCDD in this critical period to deliver research and drug discovery.
Prof Webber appointed UK DRI Director of Informatics
May 10, 2022
Congratulations to HCDD founder Caleb on his appointment to this new role leading informatics across the 750 researchers at the £290m national dementia research institute. We share the DRI's confidence that data science will lead to major breakthroughs in this area, and it is great for HCDD to be connected to the best science and methods.
Human Centric Drug Discovery welcomes experienced biotech finance director
February 9th, 2022
Human Centric Drug Discovery welcomes Kim Haworth, FCCA, MSc as company Finance Director. Kim has deep experience in biotech start-up finance including a portfolio of CFO and FD roles. She has been advising Human Centric pre-spinout and now has responsibility for all finance aspects of the company, working with the CEO. We are delighted that she is continuing her work with HCDD in this critical period to deliver financial strategy, control and management.
Human Centric Drug Discovery moves into new lab and offices
January 7, 2022
Human Centric Drug Discovery moved in to the purpose-built cell lab and offices in the Wood Centre for Innovation, just by the Churchill and John Radcliffe Hospitals and the Oxford Big Data Institute.
Human Centric Drug Discovery seed funding round complete
Friday 17th Dec 2021
Human Centric Drug Discovery raised seed funding today from Oxford Science Enterprises, following on from their initial support. The funding will enable the development of HCDD's integrated platform, building the team, and progressing internal programmes.
Human Centric Drug Discovery spins out from Oxford University
Thursday 16th December, 2021
Human Centric Drug Discovery span out of Oxford University today to push forward the work of Professors Zam Cader and Caleb Webber, including an exclusive license to the Oxford Science Enterprises funded proof of concept data. We have an exciting adventure ahead to de-risk neuroscience drug discovery using an innovative integrated platform of real-world informatics, human cellular phenotypes and genomics.